Invention Grant
- Patent Title: N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
-
Application No.: US15547779Application Date: 2016-02-15
-
Publication No.: US10173988B2Publication Date: 2019-01-08
- Inventor: Per Wikström , Erik Walum , Mona Wilcke
- Applicant: GLUCOX BIOTECH AB
- Applicant Address: SE Färentuna
- Assignee: GLUCOX BIOTECH AB
- Current Assignee: GLUCOX BIOTECH AB
- Current Assignee Address: SE Färentuna
- Agency: Bozicevic, Field & Francis LLP
- Agent James S. Keddie
- Priority: SE1550166 20150216
- International Application: PCT/SE2016/050112 WO 20160215
- International Announcement: WO2016/133446 WO 20160825
- Main IPC: C07D251/18
- IPC: C07D251/18 ; A61K31/53 ; A61P3/10 ; A61P9/00 ; A61P11/00 ; A61P25/00
Abstract:
The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine or a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase activity. A pharmaceutical composition comprising the compound.
Public/Granted literature
- US20180022715A1 N2-(3,4-DIMETHYLPHENYL)-6-((4-(P-TOLYL)PIPERAZIN-1-YL)METHYL)-1,3,5-TRIAZINE-2,4-DIAMINE Public/Granted day:2018-01-25
Information query
